We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -106.00 | -0.87% | 12,050.00 | 12,036.00 | 12,038.00 | 12,178.00 | 12,010.00 | 12,092.00 | 1,635,146 | 16:35:23 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.34 | 186.61B |
From May 2019 to May 2024
By Razak Musah Baba
LONDON--AstraZeneca PLC (AZN.LN) Friday reaffirmed its 2015 earnings guidance and said it has revised its financial reporting structure to include an additional revenue stream.
The pharmaceutical giant usually reports revenue from product sales only, with "externalization revenue" reported as operating income, it said. From January, externalization revenue, alongside product sales, will contribute to total revenue.
"Externalization revenue includes development, commercialization, partnership and out-license revenue, such as royalties and milestone receipts, together with income from services or repeatable licenses," the company said.
To reflect the change, AstraZeneca said total revenue for 2015 is expected to decline by a mid-single-digit percentage at constant exchange rates, consistent with its previous guidance.
It added that its core earnings per share are still expected to increase by a low single-digit percentage at constant exchange rates.
The company also reaffirmed that based on current exchange rates, total revenue is expected to decline by a low double-digit percentage.
Write to Razak Musah Baba at razak.baba@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
